Insights from Vector Space
Insights, scenarios and models to help you understand how artificial intelligence
is transforming the way organisations work.
Skin AI: where cosmetics end and medical devices begin
L'Oréal Beauty Genius recorded 480,000 conversations in the first six months after launch. Perfect Corp generated USD 69 million in 2025 with YouCam. Haut.AI is in partnership with Beiersdorf, NAOS Bioderma and Ulta Beauty. When AI promises diagnostics it shifts from cosmetic to medical device, falling under MDR and the high-risk EU AI Act.
Endless POCs and ROI Obsession: Where Companies Get AI Wrong
Six technical and organizational mistakes in the GenAI engineering and production phase: from compliance that blocks everything to data management, to the mistake of treating AI as a finished project.
Twelve Mistakes That Are Slowing Down AI in the Enterprise
Chinese companies have already walked the path of GenAI adoption and paid for specific mistakes. Twelve of these mistakes are documented and repeatable anywhere in the world. Knowing them in advance is invaluable.
The GenAI Use Cases You Can’t Afford to Miss in Corporate Communications
Content tailoring, audience response simulation, and disinformation intelligence are the GenAI use cases with the best value-to-feasibility ratio for communications teams. Here is why you should start here.
AI territory segmentation for the pharma sales force: the Italian prescription-data constraint
IQVIA Field Force Agent reports 27% time savings and 85% user satisfaction in 2025 early deployments. ZS ZAIDYN integrated with Salesforce Agentforce in January 2026. But Europe has no equivalent of the U.S. IQVIA Xponent: pharma territory segmentation in Italy must be built on different proxies and within union constraints on workplace mobility.
GenAI in Marketing and Communications
An analysis of 18 GenAI use cases for the communications function: which ones deliver real value, which remain hard to implement, and how to prioritize investments.
AI pharmacovigilance: the first proving ground for the EU AI Act in pharma
Oracle Argus at 19.4% of the market, ArisGlobal LifeSphere at 17.2%. NLP that codes MedDRA with AUC 0.97. The EMA Reflection Paper of September 2024 explicitly places PV within the regulated post-authorization scope. ICH E2D(R1) enters into force in the EU on March 18, 2026. Pharmacovigilance is the first pharma use case classified as high-risk.
AI Act, executive orders, Chinese laws: the world tries to rein in artificial intelligence
The US, Europe and China are building very different AI regulatory regimes. A guide to the regulatory updates every company needs to know in 2025.
AI Act and US state laws: how to build a compliance strategy that holds
The AI regulatory landscape is fragmented and rapidly evolving. EU AI Act, Colorado, Illinois, NYC, Utah: three common principles and a practical approach to avoid starting from scratch with every new law.
GenAI in the public sector: three lessons from the cases that work
Contact centers, transportation, citizen services: AI in the public sector is maturing. The cases that produce real results share three characteristics that most pilots ignore.
Personalized D2C nutraceuticals: the lesson of Care/of
Bayer acquired Care/of in 2020 for USD 225 million and shut it down in June 2024. AG1 generated USD 600 million in revenue in 2024 with a single SKU. Persona Nutrition returned to its founders and pivoted to B2B/HCP. Vitamins CAC EUR 45-80, LTV 300-600, first-month churn 20-30%. The pure quiz-subscription model is economically fragile.
Grok vs Mistral: two models, two philosophies, two different markets
xAI bets on speed of innovation and integration with X. Mistral bets on open source, digital sovereignty and efficiency. A head-to-head comparison for decision-makers.
